Search results for "phosphonates"

showing 10 items of 210 documents

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients

2010

Abstract Background Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates. Methods In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalen…

Malemedicine.medical_specialtylcsh:Specialties of internal medicineTreatment outcomeClinical NeurologyBisphosphonate-Associated Osteonecrosisstomatognathic systemlcsh:RC581-951medicinePrevalenceHumansAdverse effectGeneral DentistryMultiple myelomaAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryDentistry(all)ResearchOsteonecrosisRetrospective cohort studyMiddle Agedmedicine.diseaseDermatologySurgerystomatognathic diseasesCross-Sectional StudiesTreatment OutcomeOtorhinolaryngologyOral and maxillofacial surgeryHead and neck surgeryFemaleNeurology (clinical)businessMultiple MyelomaBisphosphonate treatmentHead & Face Medicine
researchProduct

Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis

2016

OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 25.11 months. The most c…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisDentistryOdontología03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansStage (cooking)General DentistryAgedSclerosisMedicamentoBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industry030206 dentistryMiddle AgedBisphosphonatemedicine.diseaseBone Density Conservation AgentsDenosumabOtorhinolaryngologyDental extraction030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabTomography X-Ray ComputedOsteonecrosis of the jawbusinessmedicine.drugOral Diseases
researchProduct

Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate

2005

Abstract Objective: Androgen-deprivation therapy (ADT) is the usual treatment for locally advanced or metastatic prostate cancer. Osteoporosis is a common complication of ADT. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate to prevent bone loss during androgen ablation. Methods: Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150mg. Each group was divided in 2 subgroups A1–A2 and B1–B2. All patients received calcium and cholecalciferol supplements …

Malemusculoskeletal diseasesmedicine.medical_specialtyDeoxypyridinolineBone densityBicalutamideUrologymedicine.medical_treatmentOsteoporosisUrologyImmunoenzyme TechniquesTosyl CompoundsAndrogen deprivation therapyProstate cancerchemistry.chemical_compoundAbsorptiometry PhotonBone DensityNitrilesmedicineHumansNeridronic acidAnilidesTestosteroneAmino AcidsVitamin DChromatography High Pressure LiquidAgedAged 80 and overDiphosphonatesEstradiolbusiness.industryProstatic NeoplasmsAndrogen AntagonistsPhosphorusBisphosphonatemedicine.diseaseSurgeryTreatment OutcomechemistryParathyroid HormoneOsteoporosisCalciumDrug Therapy CombinationbusinessBiomarkersFollow-Up Studiesmedicine.drug
researchProduct

LC-MS/MS characterisation and determination of dansyl chloride derivatised glyphosate, aminomethylphosphonic acid (AMPA), and glufosinate in foods of…

2021

Abstract Glyphosate and other polar and acidic pesticides have been particularly studied due to the concerns over widespread and intensive use. The chemical properties of these compounds necessitate use of customised methods, such as derivatisation or ion exchange chromatography. These approaches present a compatibility problem with ESI-MS due to presence of salts and non-volatile compounds. For that reason, a simple procedure has been developed for the extraction, pre-column derivatisation with dansyl chloride (5-(dimethylamino)naphthalene-1-sulfonyl chloride), and mass spectrometric detection of glyphosate, AMPA, and glufosinate after the separation on a C18 stationary phase. The dansyl d…

MeatClinical BiochemistryIon chromatographyOrganophosphonatesIon suppression in liquid chromatography–mass spectrometry030226 pharmacology & pharmacy01 natural sciencesBiochemistryAnalytical ChemistryMatrix (chemical analysis)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTandem Mass SpectrometryAnimalsAminomethylphosphonic acidDerivatizationDansyl CompoundsChromatographyAminobutyrates010401 analytical chemistryDansyl chlorideExtraction (chemistry)Pesticide ResiduesCell BiologyGeneral MedicineHoney0104 chemical scienceschemistryReagentCattleCucumis sativusFood AnalysisChromatography LiquidJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Mevalonate pathway: role of bisphosphonates and statins.

2011

Mevalonate; statins; bisphosphonatesSettore MED/09 - Medicina InternaMevalonatestatinbisphosphonates
researchProduct

Substituted phosphonic analogues of phenylglycine as inhibitors of phenylalanine ammonia lyase from potatoes.

2018

A series of phosphonic acid analogues of phenylglycine variously substituted in phenyl ring have been synthesized and evaluated for their inhibitory activity towards potato l-phenylalanine ammonia lyase. Most of the compounds appeared to act as moderate (micromolar) inhibitors of the enzyme. Analysis of their binding performed using molecular modeling have shown that they might be bound either in active site of the enzyme or in the non-physiologic site. The latter one is located in adjoining deep site nearby the to the entrance channel for substrate into active site.

Models MolecularaminophosphonatesMolecular modelStereochemistryPhosphorous AcidsGlycinePhenylalanine ammonia-lyase010402 general chemistryRing (chemistry)01 natural sciencesBiochemistryAmmoniachemistry.chemical_compoundStructure-Activity RelationshipPAL inhibitorsEnzyme InhibitorsPhenylalanine Ammonia-LyaseSolanum tuberosumchemistry.chemical_classificationbiologymolecular modeling010405 organic chemistryActive siteSubstrate (chemistry)General MedicineLyase0104 chemical sciencesEnzymechemistrybiology.proteinBiochimie
researchProduct

Reaction of 3-Amino-1,2,4-Triazole with Diethyl Phosphite and Triethyl Orthoformate: Acid-Base Properties and Antiosteoporotic Activities of the Prod…

2017

The reaction of diethyl phosphite with triethyl orthoformate and a primary amine followed by hydrolysis is presented, and the reaction was suitable for the preparation of (aminomethylene)bisphosphonates. 3-Amino-1,2,4-triazole was chosen as an interesting substrate for this reaction because it possesses multiple groups that can serve as the amino component in the reaction-namely, the side-chain and triazole amines. This substrate readily forms 1,2,4-triazolyl-3-yl-aminomethylenebisphosphonic acid (compound 1) as a major product, along with N-ethylated bisphosphonates as side products. The in vitro antiproliferative effects of the synthesized aminomethylenebisphosphonic acids against J774E m…

Models Molecularorganophosphorus chemistryPhosphitesBase (chemistry)FormatesTriazoleMolecular ConformationPharmaceutical ScienceOsteoclastsApoptosis010402 general chemistry01 natural sciencesAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundHydrolysisMicelcsh:Organic chemistryCell Line TumorDrug DiscoveryOrganic chemistryAnimals3-Amino-124-triazolePhysical and Theoretical Chemistrycrystallographychemistry.chemical_classificationBone Density Conservation AgentsDiphosphonates010405 organic chemistryChemistryCommunicationOrganic ChemistrySubstrate (chemistry)Triazolesthree-component reactionTriethyl orthoformateUV-Vis spectroscopyMagnetic Resonance Imaging0104 chemical sciencesP-containing drugstriazoleChemistry (miscellaneous)potentiometryaminomethylenebisphosponatesMolecular Medicineanti-proliferative activityAmine gas treatingpH-titrationbisphosphonic acidsMolecules (Basel, Switzerland)
researchProduct

Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats : a preliminary macroscopic and microsc…

2018

Background The exact pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) is still unknown. The aim of this paper was to investigate the effects of zoledronic acid and dexamethasone on the early phases of socket healing in rats subjected to tooth extractions. Material and Methods Thirty male Sprague-Dawley rats were divided into 2 groups: pharmacologically treated group (T, n=20) and non-pharmacologically treated group (C, n=10). T group rats received 0.1 mg/Kg of zoledronic acid (ZOL) and 1 mg/Kg of dexamethasone (DEX) three times a week for 10 consecutive weeks. C group rats were infused with vehicle. After 9 weeks from the first infusion, first maxillary molars were extrac…

MolarMalemedicine.medical_specialtyConnective tissueZoledronic AcidDexamethasoneBone remodelingRats Sprague-Dawley03 medical and health sciences0302 clinical medicineOsteoclastInternal medicinemedicineAnimalsHumansTooth SocketGeneral DentistryDexamethasoneDental alveolusOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchOsteonecrosis030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ratsmedicine.anatomical_structureZoledronic acidEndocrinologyOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgerybusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Mode of action of herbicidal derivatives of aminomethylenebisphosphonic acid. I. Physiologic activity and inhibition of anthocyanin biosynthesis

1996

N-Pyridylaminomethylenebisphosphonic acids constitute a class of promising herbicides. Since their mode of action at the cellular level is still poorly understood, we studied the influence of N-pyridylaminomethylenebisphosphonic acids on plant growth, at the whole plant and undifferentiated tissue levels, using seedlings and cell suspension cultures of mono- and dicotyledonous species. These compounds exhibited strong herbicidal properties, being equipotent with the popular herbicide glyphosate. Since they also depressed buckweed anthocyanin biosynthesis, the shikimate pathway could represent a site of action of N-pyridylaminomethylenebisphosphonic acids.

N-Pyridylaminomethylenebisphosphonates; Anthocyanins; Herbicides; GlyphosateN-PyridylaminomethylenebisphosphonatesPlant physiologyPlant ScienceBiologyanthocyaninschemistry.chemical_compoundMetabolic pathwayherbicidesglyphosatechemistryMechanism of actionBiochemistryBiosynthesisAnthocyaninGlyphosatemedicineShikimate pathwaymedicine.symptomMode of actionAgronomy and Crop ScienceJournal of Plant Growth Regulation
researchProduct